细胞的命运:间充质干细胞的药代动力学

The Fate of Cells: Pharmacokinetics of MSC

细胞药物已成为药物研发中最新的领域之一。由于细胞药物具有增殖和自主趋化的能力,其体内药学特征与传统的小分子和大分子药物差异很大。目前,虽然细胞药物已经开始走向临床,但是对于细胞类药物进入体内之后的命运变化普遍缺乏认识。如果能够借助药代动力学理论,预测不同细胞药物的体内分布、代谢/排泄规律,进而在细胞药物进入机体之后的动态分布和细胞疗效之间建立关系,将有效提高细胞药物的临床疗效,降低风险,减少药物的相互作用。在该文中,我们以间充质干细胞(mesenchymal stem cell,MSC)为例,整理了现有的一些研究成果,试图对细胞药物的药代动力学和其药效、毒效的关系进行归纳,为今后进一步探索细胞药物在体内的命运奠定基础。

Recently, cellular drugs have become one of the hottest areas in drug development. Cellular drugs are quite different from the traditional small molecules and macromolecular drugs, because of their proliferation and chemotactic abilities. With the help of pharmacokinetic theories, it would be feasible to describe and predict the fate of cell drug, characterize their distribution, metabolism, and elimination in the body. That will improve the clinical efficacy and safety of the cellular drugs, reduce the risk of drug-drug interactions. In this paper, we take mesenchymal stem cell（MSC） as an example, trying to clarify the relationship between the pharmacokinetics and the efficacy/toxicity（PK/PD/TD） of cell drugs according to published literatures.